摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-Methyl-3-propyl-[1,2,4]oxadiazole | 89600-64-6

中文名称
——
中文别名
——
英文名称
5-Methyl-3-propyl-[1,2,4]oxadiazole
英文别名
5-Methyl-3-propyl-1,2,4-oxadiazole
5-Methyl-3-propyl-[1,2,4]oxadiazole化学式
CAS
89600-64-6
化学式
C6H10N2O
mdl
——
分子量
126.158
InChiKey
BHEWJAIXUMSOCL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    9
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.67
  • 拓扑面积:
    38.9
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
    申请人:OOST Thorsten
    公开号:US20140057916A1
    公开(公告)日:2014-02-27
    This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.
    这项发明涉及式1的取代4-吡啶酮及其作为中性粒细胞弹性蛋白酶活性抑制剂的用途,包含这些化合物的药物组合物,以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
  • FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS
    申请人:Corkey Britton Kenneth
    公开号:US20120289493A1
    公开(公告)日:2012-11-15
    The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the compounds is given by Formula I: wherein Q, R 1 , X 1 , X 2 , Y and R 2 are as described herein, to methods for the preparation and use of the compounds and to pharmaceutical compositions containing the same.
    本公开涉及一类为通道抑制剂的化合物,以及它们在治疗各种疾病状态中的应用,包括心血管疾病和糖尿病。在特定实施例中,该化合物的结构由式I给出: 其中Q、R1、X1、X2、Y和R2如本文所述,以及制备和使用该化合物的方法,以及含有该化合物的药物组合物。
  • [EN] URACIL CONTAINING COMPOUNDS<br/>[FR] COMPOSÉS CONTENANT DE L'URACILE
    申请人:CV6 THERAPEUTICS NI LTD
    公开号:WO2018128720A1
    公开(公告)日:2018-07-12
    Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.
    提供的是dUTPase抑制剂,包含此类化合物的组合物以及使用此类化合物和组合物的方法。
  • [EN] 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS<br/>[FR] COMPOSÉS 1H-PYRAZOLO[4,3-D]PYRIMIDINE UTILES EN TANT QU'AGONISTES DU RÉCEPTEUR DE TYPE TOLL 7 (TLR7)
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2021154668A1
    公开(公告)日:2021-08-05
    Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). (I) Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.
    根据公式I,化合物可用作Toll样受体7(TLR7)的激动剂。这些化合物可用于癌症治疗,特别是与抗癌免疫疗法药物联合使用,或作为疫苗佐剂。
  • 2,3-DIHYDROFURO[2,3-c]PYRIDINES, THEIR USE AS MODULATORS OF THE G-PROTEIN-COUPLED RECEPTOR GPR119 AND PHARMACEUTICAL COMPOSITIONS THEREOF
    申请人:ECKHARDT Matthias
    公开号:US20130296354A1
    公开(公告)日:2013-11-07
    The present invention relates to compounds of general formula I, wherein the groups R 1 and A are as defined in the application, which have valuable pharmacological properties, and in particular bind to the GPR119 receptor and modulate its activity.
    本发明涉及一般式I的化合物,其中R1和A是在申请中定义的基团,具有有价值的药理特性,特别是能够结合到GPR119受体并调节其活性。
查看更多